PhenomeX Inc.: Nasdaq/NYSE listing notice — PhenomeX receives Nasdaq notice for non-compliance with minimum bid price rule

PhenomeX Inc.

Notice on June 21, 2023: bid price below $1.00 for 30 consecutive business days.
Company has 180 days, until Dec 12, 2023, to regain compliance by closing at $1.00+ for 10 days.
If not compliant by deadline, may transfer to Nasdaq Capital Market for an additional 180-day period.
Company may consider a reverse stock split or other options to cure the deficiency.
There is no immediate effect on trading; stock remains on Nasdaq Global Select Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

PhenomeX Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

June 21, 2023, PhenomeX Inc. (the “Company”) received a notice (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) that the Company is not in compliance with Nasdaq’s Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”), because the minimum bid price of the Company’s common stock has been below $1.00 per share for 30 consecutive business days. The Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until December 12, 2023, to re

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-074232

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.